ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
As part of an expansion push that emphasizes the European market, the biopharmaceutical company Amgen announced plans last week to invest more than $1 billion in new process development, bulk manufacturing, and packaging facilities in Cork, Ireland. The company is also adding facilities in Puerto Rico to produce the anemia drugs Epogen and Aranesp. Amgen says it will expand its existing research and development operations in Cambridge, Mass.; San Francisco; Seattle; and Cambridge, England, and it plans to build a new development center in Uxbridge, England. Meanwhile, Amgen has moved its European headquarters from Lucerne to Zug, Switzerland. Amgen says it hopes to employ 1,100 workers at the new Cork plant by 2010.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter